The new class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which stimulate the pancreas to make more insulin after eating a meal, may be changing the way we treat people with type 2 diabetes. Join guest host, Dr. Candis Morello and her guest, professor of clinical pharmacy in the School of Pharmacy at the University of California San Francisco, Dr. Lisa Kroon, as they discuss the use of DPP-4 therapy in the treatment of type 2 diabetes.
DPP-4 Inhibitors: A New Class of Medications
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The new class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which stimulate the pancreas to make more insulin after eating a meal, may be changing the way we treat people with type 2 diabetes. Join guest host, Dr. Candis Morello and her guest, professor of clinical pharmacy in the School of Pharmacy at the University of California San Francisco, Dr. Lisa Kroon, as they discuss the use of DPP-4 therapy in the treatment of type 2 diabetes.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Updates From the 7th World Symposium Task Force
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?